Puma Biotechnology Alisertib , an Aurora Kinase A Inhibitor
Find a Job | Puma Biotechnology, Inc.
Why Puma Biotechnology (PBYI) Stock Is Surging Today - TheStreet
Puma biotech and Specialised Therapeutics signs agreement to commercialize NERLYNX®
Biotech Premarket Movers: Aurinia (AUPH), Puma (PBYI), PTC (PTCT), Juno (JUNO) - TheStreet
Takeda offloads cancer drug to Puma
Puma Biotechnology, Knight Therapeutics sign license deal to commercialize NERLYNX in Canada - Pharmaceutical Business review
Puma Biotechnology Reports Third Quarter 2021 Financial Results | Business Wire
Puma Biotechnology | $PBYI Stock | Shares Climb Up as Company Announced FDA Approval for NERLYNX - Warrior Trading News
Puma Biotechnology and Specialised Therapeutics Asia Enter into Exclusive Licensing Agreement to Commercialize NERLYNX® (nerati
Puma Biotechnology (PBYI) Presents At Barclays Global Healthcare Virtual Conference (NASDAQ:PBYI) | Seeking Alpha
Puma Biotech (PBYI) Hoping for a Bounce at Annual Meeting of Cancer Society - TheStreet
PUMA Background
Focus Areas - Department of Molecular Pharmacology and Experimental Therapeutics Research - Mayo Clinic Research
Puma Biotechnology Presents P-II (SUMMIT) Basket Trial Results of Neratinib for EGFR Exon 18-Mutant NSCLC at EORTC/NCI/AACR 2022
CANbridge Pharmaceuticals and Puma Biotechnology Agree to Terminate NERLYNX® License Agreement and Settle Arbitration | Business Wire
Articles with Puma Biotechnology
Puma Biotech Plunges on Sharp Drop in Cancer-Drug Sales - TheStreet
Susan Malecha - Senior Director, Medical Affairs - Puma Biotechnology, Inc. | LinkedIn
Puma Biotech punts near $300 million on Takeda discard
APHINITY' Study Spells Major Trouble for Roche, Another Win for Puma Bio - TheStreet
